D. J. Abraham and J. Varga, Scleroderma: from cell and molecular mechanisms to disease models, Trends Immunol, vol.26, pp.587-95, 2005.

M. Elhai, C. Meune, J. Avouac, A. Kahan, and Y. Allanore, Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies, Rheumatol Oxf Engl, vol.51, pp.1017-1043, 2012.

J. Varga, M. Trojanowska, and M. Kuwana, Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities, J Scleroderma Relat Disord, vol.2, pp.137-52, 2017.

J. Varga and B. Pasche, Transforming growth factor beta as a therapeutic target in systemic sclerosis, Nat Rev Rheumatol, vol.5, pp.200-206, 2009.

P. S. Linsley and J. A. Ledbetter, The role of the CD28 receptor during T cell responses to antigen, Annu Rev Immunol, vol.11, pp.191-212, 1993.

J. A. Bluestone, New perspectives of CD28-B7-mediated T cell costimulation, Immunity, vol.2, pp.555-564, 1995.

J. J. Goronzy and C. M. Weyand, T-cell co-stimulatory pathways in autoimmunity, Arthritis Res Ther, vol.10, 2008.

A. H. Sharpe and G. J. Freeman, The B7-CD28 superfamily, Nat Rev Immunol, vol.2, pp.116-142, 2002.

N. Pilat, M. H. Sayegh, and T. Wekerle, Costimulatory pathways in transplantation, Semin Immunol, vol.23, pp.293-303, 2011.

E. A. Tivol, F. Borriello, A. N. Schweitzer, W. P. Lynch, J. A. Bluestone et al., Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4, Immunity, vol.3, pp.90125-90131, 1995.

J. R. Podojil and S. D. Miller, Molecular mechanisms of T cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy, Immunol Rev, vol.229, pp.337-55, 2009.

M. Hebbar, P. Jeannin, G. Magistrelli, P. Hatron, E. Hachulla et al., Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosis, Clin Exp Immunol, vol.136, pp.388-92, 2004.

P. Gourh, F. C. Arnett, F. K. Tan, S. Assassi, D. Divecha et al., Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis, Ann Rheum Dis, vol.69, pp.550-555, 2010.

S. Sato, M. Fujimoto, M. Hasegawa, K. Komura, K. Yanaba et al., Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis, Rheumatol Oxf Engl, vol.43, pp.1261-1267, 2004.

R. W. Stuart and M. K. Racke, Targeting T cell costimulation in autoimmune disease, Expert Opin Ther Targets, vol.6, pp.275-89, 2002.

A. T. Dantas, A. R. De-almeida, M. Sampaio, M. F. Cordeiro, P. De-oliveira et al., Different profile of cytokine production in patients with systemic sclerosis and association with clinical manifestations, Immunol Lett, vol.198, pp.12-18, 2018.

J. H. Ruth, J. B. Rottman, G. A. Kingsbury, A. J. Coyle, G. K. Haines et al., ICOS and B7 costimulatory molecule expression identifies activated cellular subsets in rheumatoid arthritis, Cytom Part J Int Soc Anal Cytol, vol.71, pp.317-343, 2007.

A. Hutloff, K. Büchner, K. Reiter, H. J. Baelde, M. Odendahl et al., Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus, Arthritis Rheum, vol.50, pp.3211-3231, 2004.

S. Wang, G. Zhu, A. I. Chapoval, H. Dong, K. Tamada et al., Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS, Blood, vol.96, pp.2808-2821, 2000.

K. Yanaba, Y. Asano, S. Noda, K. Akamata, N. Aozasa et al., Increased production of soluble inducible costimulator in patients with diffuse cutaneous systemic sclerosis, Arch Dermatol Res, vol.305, pp.17-23, 2013.

M. Hasegawa, M. Fujimoto, T. Matsushita, Y. Hamaguchi, and K. Takehara, Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis, Rheumatol Oxf Engl, vol.52, pp.242-51, 2013.

C. Nohara, H. Akiba, A. Nakajima, A. Inoue, C. S. Koh et al., Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells, J Immunol Baltim Md, vol.1950, pp.2108-2123, 2001.

O. D'orlando, G. Gri, G. Cattaruzzi, S. Merluzzi, E. Betto et al., Outside inside signalling in CD40-mediated B cell activation, J Biol Regul Homeost Agents, vol.21, pp.49-62, 2007.

K. Komura, A. Yoshizaki, M. Kodera, Y. Iwata, F. Ogawa et al., Increased serum soluble OX40 in patients with systemic sclerosis, J Rheumatol, vol.35, pp.2359-62, 2008.

L. Bossini-castillo, J. Broen, C. P. Simeon, L. Beretta, M. C. Vonk et al., A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort, Ann Rheum Dis, vol.70, pp.638-679, 2011.

M. Elhai, J. Avouac, A. M. Hoffmann-vold, N. Ruzehaji, O. Amiar et al., OX40L blockade protects against inflammation-driven fibrosis, Proc Natl Acad Sci, vol.113, pp.3901-3911, 2016.

W. Peng, J. Yan, Y. Wan, B. Wang, J. Tao et al., Matrix metalloproteinases: a review of their structure and role in systemic sclerosis, J Clin Immunol, vol.32, pp.1409-1423, 2012.

E. Godefroy, A. Gallois, J. Idoyaga, M. Merad, N. Tung et al., Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses, Cell Rep, vol.9, pp.1856-70, 2014.

E. Godefroy, O. Manches, B. Dréno, T. Hochman, L. Rolnitzky et al., Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12-and OX40L-dependent pathway, Cancer Cell, vol.19, pp.333-379, 2011.

G. Valentini, M. F. Romano, C. Naclerio, R. Bisogni, A. Lamberti et al., Increased expression of CD40 ligand in activated CD4+ T lymphocytes of systemic sclerosis patients, J Autoimmun, vol.15, pp.61-67, 2000.

C. Fukasawa, Y. Kawaguchi, M. Harigai, T. Sugiura, K. Takagi et al., Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): role of CD40-CD154 in the phenotype of SSc fibroblasts, Eur J Immunol, vol.33, pp.2792-800, 2003.

K. Komura, M. Fujimoto, T. Matsushita, K. Yanaba, M. Kodera et al., Increased serum soluble CD40 levels in patients with systemic sclerosis, J Rheumatol, vol.34, pp.353-361, 2007.

J. Jun, T. Kim, Y. Na, and D. Yoo, High expression of CD40 on skin fibroblasts from patients with systemic sclerosis, Rheumatol Int, vol.28, pp.95-102, 2007.

X. Lian, R. Xiao, X. Hu, T. Kanekura, H. Jiang et al., DNA demethylation of CD40l in CD4+ T cells from women with systemic sclerosis: a possible explanation for female susceptibility, Arthritis Rheum, vol.64, pp.2338-2383, 2012.

Y. Luo, Y. Wang, Y. Shu, Q. Lu, and R. Xiao, Epigenetic mechanisms: an emerging role in pathogenesis and its therapeutic potential in systemic sclerosis, Int J Biochem Cell Biol, vol.67, pp.92-100, 2015.

Y. Allanore, D. Borderie, C. Meune, H. Lemaréchal, S. Weber et al., Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers, Ann Rheum Dis, vol.64, pp.481-484, 2005.

Y. Yalçinkaya, S. Adin-Çinar, B. Artim-esen, S. Kamali, Ö. Pehlivan et al., Capillaroscopic findings and vascular biomarkers in systemic sclerosis: association of low CD40L levels with late scleroderma pattern, Microvasc Res, vol.108, pp.17-21, 2016.

D. J. Haddon, H. E. Wand, J. A. Jarrell, R. F. Spiera, P. J. Utz et al., Proteomic analysis of sera from individuals with diffuse cutaneous systemic sclerosis reveals a multianalyte signature associated with clinical improvement during imatinib mesylate treatment, J Rheumatol, vol.44, pp.631-639, 2017.

J. Avouac, M. Elhai, M. Tomcik, B. Ruiz, M. Friese et al., Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis, Ann Rheum Dis, vol.72, pp.1089-98, 2013.

P. Dieudé, M. Guedj, M. E. Truchetet, J. Wipff, L. Revillod et al., Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis, Arthritis Rheum, vol.63, pp.1097-105, 2011.

L. Bossini-castillo, C. P. Simeon, L. Beretta, J. C. Broen, M. C. Vonk et al., A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis, Arthritis Res Ther, vol.14, p.85, 2012.

M. Ayano, H. Tsukamoto, K. Kohno, N. Ueda, A. Tanaka et al., Increased CD226 expression on CD8+ t cells is associated with upregulated cytokine production and endothelial cell injury in patients with systemic sclerosis, J Immunol Baltim Md, vol.195, pp.892-900, 1950.

M. A. Postow, R. Sidlow, and M. D. Hellmann, Immune-related adverse events associated with immune checkpoint blockade, N Engl J Med, vol.378, pp.158-68, 2018.

N. S. Barbosa, D. A. Wetter, C. N. Wieland, N. K. Shenoy, S. N. Markovic et al., Scleroderma induced by pembrolizumab: a case series

, Mayo Clin Proc, vol.92, pp.1158-63, 2017.

B. J. Tjarks, A. M. Kerkvliet, A. D. Jassim, and J. S. Bleeker, Scleroderma-like skin changes induced by checkpoint inhibitor therapy, J Cutan Pathol, vol.45, pp.615-623, 2018.

T. L. Walunas, D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman et al., CTLA-4 can function as a negative regulator of T cell activation, Immunity, vol.1, pp.405-418, 1994.

D. Saverino, R. Simone, M. Bagnasco, and G. Pesce, The soluble CTLA-4 receptor and its role in autoimmune diseases: an update, Auto Immun Highlights, vol.1, pp.73-81, 2010.

G. G. Song and Y. H. Lee, The CTLA-4 and MCP-1 polymorphisms and susceptibility to systemic sclerosis: a meta-analysis, Immunol Invest, vol.42, pp.481-92, 2013.

G. Stifano and R. B. Christmann, Macrophage involvement in systemic sclerosis: do we need more evidence?, Curr Rheumatol Rep, vol.18, 2016.

G. Yu, L. Bu, Y. Zhao, L. Mao, W. Deng et al., CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma, Oncoimmunology, vol.5, p.1151594, 2016.

S. Dai, R. Jia, X. Zhang, Q. Fang, and L. Huang, The PD-1/PD-Ls pathway and autoimmune diseases, Cell Immunol, vol.290, pp.72-81, 2014.

K. Yanaba, M. Hayashi, Y. Yoshihara, and H. Nakagawa, Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: association with extent of skin sclerosis, J Dermatol, vol.43, pp.954-961, 2016.

T. Fukasawa, A. Yoshizaki, S. Ebata, K. Nakamura, R. Saigusa et al., Contribution of soluble forms of programmed death 1 and programmed death ligand 2 to disease severity and progression in systemic sclerosis, Arthritis Rheumatol, vol.69, pp.1879-90, 2017.

D. Khanna, J. Distler, P. Sandner, and O. Distler, Emerging strategies for treatment of systemic sclerosis, J Scleroderma Relat Disord, vol.1, pp.186-93, 2016.

M. Rabieyousefi, P. Soroosh, K. Satoh, F. Date, N. Ishii et al., Indispensable roles of OX40L-derived signal and epistatic genetic effect in immune-mediated pathogenesis of spontaneous pulmonary hypertension, BMC Immunol, vol.12, p.67, 2011.

H. A. Blair and E. D. Deeks, Abatacept: a review in rheumatoid arthritis, Drugs, vol.77, pp.1221-1254, 2017.

M. Ponsoye, C. Frantz, N. Ruzehaji, C. Nicco, M. Elhai et al., Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis, Ann Rheum Dis, vol.75, pp.2142-2151, 2016.

B. Web, , 2018.

M. Elhai, M. Meunier, M. Matucci-cerinic, B. Maurer, G. Riemekasten et al., Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study, Ann Rheum Dis, vol.72, 2013.

F. V. De-paoli, B. D. Nielsen, F. Rasmussen, B. Deleuran, and K. Søndergaard, Abatacept induces clinical improvement in patients with severe systemic sclerosis, Scand J Rheumatol, vol.43, pp.342-347, 2014.

E. F. Chakravarty, V. Martyanov, D. Fiorentino, T. A. Wood, D. J. Haddon et al., Gene expression changes reflect clinical response in a placebocontrolled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis, Arthritis Res Ther, vol.17, p.159, 2015.

M. Khraishi, A. Russell, and W. P. Olszynski, Safety profile of abatacept in rheumatoid arthritis: a review, Clin Ther, vol.32, 2010.